U.K. selects first drugs for pathfinding antimicrobial resistance initiative

The U.K. continues to be a leader in combatting what could be the next pandemic — one brought on by the failure of the market for antimicrobials. On Friday, NHS England and NHS Improvement selected the first antimicrobial drugs to be purchased via the country’s groundbreaking subscription-based payment model.

Zavicefta ceftazidime/avibactam from Pfizer Inc. (NYSE:PFE) and Fetcroja cefiderocol (Fetroja — U.S.) from Shionogi & Co. Ltd. (Tokyo:4507) now advance to an innovative health technology evaluation process that will be run by NICE during the next 12 months. NICE and the Department of Health and Social Care are working with NHS England and Improvement on the initiative...